{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$7.55 vs. cons $7.22",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Insurance benefit ratio",
      "prediction": "IN-LINE",
      "answer": "pred ~90.9% vs. cons 91.2%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$40.85B vs. cons $40.61B",
      "confidence": "HIGH"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$9.50 vs. cons $8.94 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Insurance benefit ratio",
      "prediction": "BETTER",
      "answer": "guide ~92.50% vs. cons 92.75% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 revenue",
      "prediction": "LOWER",
      "answer": "guide ~$161.0B vs. cons $162.19B (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.0,
  "day5_path": "FADE",
  "day5_rationale": "Day-1 residual of +3.8% fades to a five-day residual of +2.0%: favorable Q2 medical costs and a modest FY2026 raise support the initial move, but 2027 benefit reductions and likely membership attrition constrain out-period EPS revisions after the beat.",
  "day5_confidence": "MEDIUM"
}